Efficacy and safety of Anlotinib combined with icotinib in the treatment of advanced non-small-cell lung cancer

Hualin Chen¹, Yiping Luo¹, Muwen Lin¹, Xiaoxia Peng¹, Meilian Liu¹, Zhong Huang¹, Yongcun Wang¹, Shujun Li¹, Donghong Yang^2,*, Zhixiong Yang^1,*

¹Department of Pulmonary Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524023, Guangdong, China - ²Department of Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524023, Guangdong, China

Introduction: We aimed to explore the efficacy and safety of Anlotinib combined with icotinib in the treatment of advanced non-small-cell lung cancer (NSCLC). 

Materials and methods: 23 patients with local advanced/advanced NSCLC with epidermal growth factor receptor (EGFR)-positive were included in this study. All patients received oral icotinib and anlotinib. 

Results: The disease control rate of the whole population was 78%. The progression-free survival (PFS) rate at the 20th month was 70.58%. Moreover, the average medication cycle of the whole population was (13.2 ± 7.8), and the median medication cycle was 10(1-38). The most common adverse reactions were hypertension (47.83%) and hand-foot syndrome (43.48%). There were three cases of grade 3 adverse reactions, including hand-foot syndrome, hypertension, and diarrhea. 

Conclusion: For patients with local advanced/advanced NSCLC with EGFR-positive, Anlotinib combined with icotinib can not only delay the drug resistance to achieve better clinical efficacy, but also has good safety and tolerability.